TWST
Twist Bioscience Corp
+17.46 (+12.20%)160.53USD1.7M成交股數10.1B市值–本益比(近四季)23.3股價營收比+23.2%營收年增(近四季)2026-11-16下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 9 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 118M+23% | 111M+19% | 104M+17% | 99.0M+22% | 96.1M+28% | 92.8M+30% | 88.7M+33% | 81.5M+28% | 75.3M | 71.5M | 66.9M | 63.7M |
| 營業成本 | 55.9M | 53.6M | 49.7M | 48.2M | 44.8M | 46.8M | 45.9M | 46.2M | 44.4M | 42.5M | 42.4M | 41.8M |
| 毛利 | 62.5M+22% | 57.1M+24% | 54.0M+26% | 50.8M+44% | 51.3M+66% | 46.0M+59% | 42.8M+75% | 35.3M+61% | 30.9M | 29.0M | 24.5M | 21.9M |
| 毛利率 | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | 49.6% | 48.3% | 43.3% | 41.0% | 40.5% | 36.6% | 34.4% |
| 研發費用 | 18.0M | 19.7M | 17.1M | 17.0M | 18.0M | 23.9M | 21.3M | 22.5M | 24.1M | 23.1M | 23.7M | 24.5M |
| 銷售管理費用 | 80.7M | 76.1M | 69.7M | 63.8M | 63.4M | 63.7M | 56.2M | 56.8M | 55.6M | 52.8M | 47.4M | 46.1M |
| 營業利益 | −36.3M+20% | −45.9M+10% | −32.9M-5% | −29.9M-66% | −30.1M-38% | −41.6M-12% | −34.6M-31% | −88.9M+46% | −48.9M | −47.0M | −50.1M | −60.8M |
| 營業利益率 | -30.6% | -41.4% | -31.7% | -30.2% | -31.4% | -44.8% | -39.1% | -109.2% | -64.9% | -65.7% | -74.9% | -95.4% |
| 稅後淨利 | −35.1M-272% | −44.0M+12% | −30.5M-3% | −27.1M-68% | 20.4M-145% | −39.3M-9% | −31.6M-32% | −85.6M+49% | −45.5M | −43.0M | −46.2M | −57.4M |
| 淨利率 | -29.6% | -39.8% | -29.4% | -27.4% | 21.2% | -42.4% | -35.6% | -105.0% | -60.4% | -60.2% | -69.1% | -90.0% |
| 稀釋 EPS | -0.56-270% | -0.71+8% | -0.50-6% | -0.44-70% | 0.33-142% | -0.66-12% | -0.53-35% | -1.47+46% | -0.79 | -0.75 | -0.81 | -1.01 |
| 稀釋股數 | 62.4M | 61.7M | 61.1M | 59.8M | 61.2M | 59.6M | 59.2M | 58.1M | 57.8M | 57.5M | 56.9M | 57.0M |
資產負債表 期末餘額
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 117M | 123M | 149M | 183M | 201M | 210M | 221M | 239M | 243M | 266M | 286M | 307M |
| 應收帳款 | 65.1M | 64.2M | 50.1M | 57.0M | 49.9M | 49.9M | 39.3M | 32.0M | 36.0M | 35.4M | 44.1M | 42.6M |
| 存貨 | 35.2M | 33.5M | 32.9M | 28.3M | 25.9M | 20.9M | 23.5M | 28.5M | 30.4M | 30.9M | 32.1M | 36.4M |
| 總資產 | 672M | 676M | 638M | 642M | 644M | 596M | 609M | 638M | 703M | 733M | 776M | 810M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 227M | 221M | 182M | 169M | 165M | 156M | 153M | 147M | 143M | 143M | 153M | 153M |
| 股東權益 | 446M | 455M | 456M | 473M | 478M | 440M | 456M | 491M | 560M | 590M | 623M | 658M |
| 負債比 | 33.7% | 32.7% | 28.5% | 26.3% | 25.7% | 26.1% | 25.1% | 23.0% | 20.3% | 19.5% | 19.7% | 18.9% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | −24.8M+16% | – | – | – | −21.4M | – | – | −23.0M | – | – |
| 資本支出 | – | – | 10.0M | – | – | – | 2.3M | – | – | 1.5M | – | – |
| 自由現金流 | – | – | −34.8M+47% | – | – | – | −23.7M | – | – | −24.5M | – | – |
| 折舊攤銷 | – | – | 6.2M | – | – | – | 6.4M | – | – | 8.2M | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | -33.5% | – | – | – | -26.7% | – | – | -34.2% | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 377M
| Reportable | 377M | 100.0% | +20.3% |
|---|
地區2025 年度 · 377M
| 美洲 | 226M | 59.9% | +16.3% |
|---|---|---|---|
| 歐洲中東非洲 | 124M | 33.0% | +34.2% |
| 亞太 | 26.8M | 7.1% | +0.9% |
產品／服務2025 年度 · 377M
| Ngs Tools | 208M | 55.3% | +23.0% |
|---|---|---|---|
| Synthetic Genes | 114M | 30.2% | +22.6% |
| Antibody Discovery | 23.5M | 6.2% | +15.4% |
| Oligo Pools | 20.2M | 5.4% | +19.7% |
| Dna And Biopharma Libraries | 11.2M | 3.0% | -19.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 377M | +20.3% | −77.7M | -20.6% | -1.30 | −75.6M |
| FY2024 | 313M | +27.7% | −209M | -66.7% | -3.60 | −69.2M |
| FY2023 | 245M | +20.4% | −205M | -83.5% | -3.60 | −170M |
| FY2022 | 204M | +53.8% | −218M | -107.0% | -4.04 | −226M |
| FY2021 | 132M | +46.9% | −152M | -114.9% | -3.15 | −139M |
| FY2020 | 90.1M | +65.7% | −140M | -155.3% | -3.57 | −152M |
| FY2019 | 54.4M | +113.9% | −108M | -198.0% | -3.92 | −103M |
| FY2018 | 25.4M | – | −71.2M | -280.2% | -25.51 | −69.9M |